Released Aug 13, 2020, during market hours
10-Q filed Aug 13, 2020, 44 days after period end · 0001564590-20-039951
Q2 2020 · 10-Q
Revenue—
Net Income-$5.56M-$5.56M N/M vs Q2 2019N/M vs Q1 2020
EPS Diluted-$0.41-$0.41 N/M vs Q2 2019N/M vs Q1 2020
Operating Income-$5,070,000N/M
Operating Cash Flowderived-$5,300,000—
Free Cash Flowderived-$5,304,000—
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-Q.
Same quarter
| Metric | Q2 2020 | Q2 2019 |
|---|---|---|
| Net Income | -$5.56M | -$8.81M |
| EPS Diluted | -$0.41 | -$1.33 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Compass Therapeutics, Inc. · CIK 1738021 · Engraved from SEC EDGAR